These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30243754)

  • 41. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.
    Burgio SL; Conteduca V; Rudnas B; Carrozza F; Campadelli E; Bianchi E; Fabbri P; Montanari M; Carretta E; Menna C; De Giorgi U
    Clin Genitourin Cancer; 2015 Feb; 13(1):39-43. PubMed ID: 24999168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
    Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
    [No Abstract]   [Full Text] [Related]  

  • 43. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
    Verzoni E; De Giorgi U; Derosa L; Caffo O; Boccardo F; Facchini G; Porcu L; De Vincenzo F; Zaniboni A; Chiuri VE; Fratino L; Santini D; Adamo V; De Vivo R; Dinota A; Messina C; Ricotta R; Caserta C; Scavelli C; Susi M; Tartarone A; Surace G; Mosca A; Bruno M; Barni S; Grassi P; Procopio G
    Oncotarget; 2016 Jun; 7(26):40085-40094. PubMed ID: 27223078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
    Bonnet C; Boudou-Rouquette P; Azoulay-Rutman E; Huillard O; Golmard JL; Carton E; Noé G; Vidal M; Orvoen G; Chah Wakilian A; Villeminey C; Blanchet B; Alexandre J; Goldwasser F; Thomas-Schoemann A
    Cancer Chemother Pharmacol; 2017 May; 79(5):1051-1055. PubMed ID: 28361167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
    J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.
    Gunduz S; Bozcuk H; Yıldız M; Goksu SS; Uysal M; Arslan D; Tatlı AM; Mutlu H; Coşkun HS; Ozdogan M
    Indian J Cancer; 2015; 52(4):658-60. PubMed ID: 26960509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.
    Francini E; Fiaschi AI; Petrioli R; Bianco V; Laera L; Francini F; Roviello G
    Anticancer Drugs; 2015 Sep; 26(8):910-1. PubMed ID: 26207428
    [No Abstract]   [Full Text] [Related]  

  • 51. Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
    Francini E; Sweeney CJ
    Eur Urol; 2016 Sep; 70(3):410-2. PubMed ID: 27184379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice.
    Woo HH; Begbie S; Gogna K; Mainwaring PN; Murphy DG; Parnis F; Steer C; Davis ID
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):228-36. PubMed ID: 25132163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
    Carton E; Noe G; Huillard O; Golmard L; Giroux J; Cessot A; Saidu NE; Peyromaure M; Zerbib M; Narjoz C; Guibourdenche J; Thomas A; Vidal M; Goldwasser F; Blanchet B; Alexandre J
    Eur J Cancer; 2017 Feb; 72():54-61. PubMed ID: 28027516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.
    Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SM
    J Geriatr Oncol; 2016 Mar; 7(2):81-9. PubMed ID: 26853769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial.
    Bultijnck R; Deforche B; Borrey N; Van Bauwel J; Lievens M; Rammant E; Fonteyne V; Decaestecker K; Steyaert A; Lumen N; Ost P
    World J Urol; 2021 Feb; 39(2):357-364. PubMed ID: 32008114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resisting resistance: Establishing new treatment options for CRPC patients.
    Beedie S; Figg WD
    Cancer Biol Ther; 2016 Apr; 17(4):337-8. PubMed ID: 26828765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients' and partners' views of care and treatment provided for metastatic castrate-resistant prostate cancer in the UK.
    Catt S; Matthews L; May S; Payne H; Mason M; Jenkins V
    Eur J Cancer Care (Engl); 2019 Nov; 28(6):e13140. PubMed ID: 31475410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study.
    Jenkins V; Solis-Trapala I; Payne H; Mason M; Fallowfield L; May S; Matthews L; Catt S
    Clin Oncol (R Coll Radiol); 2019 Feb; 31(2):99-107. PubMed ID: 30473408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.
    Gallaher J; Cook LM; Gupta S; Araujo A; Dhillon J; Park JY; Scott JG; Pow-Sang J; Basanta D; Lynch CC
    Clin Exp Metastasis; 2014 Dec; 31(8):991-9. PubMed ID: 25173680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory.
    Gluzman M; Scott JG; Vladimirsky A
    Proc Biol Sci; 2020 Apr; 287(1925):20192454. PubMed ID: 32315588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.